$4.11
0.03[0.74%]
At close: Apr 26
$4.11
0[0.00%]
After Hours: 6:50PM EDT
Autolus Therapeutics
(NASDAQ:AUTL)Autolus Therapeutics Stock (NASDAQ:AUTL), Analyst Ratings, Price Targets, Predictions
Autolus Therapeutics PLC has a consensus price target of $10.09, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Needham, Truist Securities, and Truist Securities on April 12, 2024, April 9, 2024, and March 18, 2024. With an average price target of $10 between Needham, Truist Securities, and Truist Securities, there's an implied 143.31% upside for Autolus Therapeutics PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Truist Securities
Goldman Sachs
Deutsche Bank
Truist Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Autolus Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 118.98% | Needham | Gil Blum | → $9 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 167.64% | Truist Securities | Gil Blum | $10 → $11 | Maintains | Buy | Get Alert |
| 03/18/2024 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 143.31% | Truist Securities | Gil Blum | $9 → $10 | Maintains | Buy | Get Alert |
| 03/14/2024 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 118.98% | Needham | Gil Blum | $9 → $9 | Maintains | Buy | Get Alert |
| 02/12/2024 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 118.98% | Needham | Gil Blum | $8 → $9 | Maintains | Buy | Get Alert |
| 01/22/2024 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 94.65% | Needham | Gil Blum | $7 → $8 | Maintains | Buy | Get Alert |
| 12/13/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 16.79% | Goldman Sachs | — | $3.2 → $4.8 | Maintains | Neutral | Get Alert |
| 11/29/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 70.32% | Needham | Gil Blum | → $7 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 143.31% | Deutsche Bank | James Shin | → $10 | Initiates | → Buy | Get Alert |
| 10/25/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 70.32% | Needham | Gil Blum | → $7 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 118.98% | Truist Securities | Asthika Goonewardene | $6 → $9 | Maintains | Buy | Get Alert |
| 06/05/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 70.32% | Needham | Gil Blum | → $7 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 70.32% | Needham | Gil Blum | → $7 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 45.99% | Wells Fargo | Vanck Zhu | $8 → $6 | Maintains | Overweight | Get Alert |
| 05/05/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 70.32% | Needham | Gil Blum | → $7 | Reiterates | → Buy | Get Alert |
| 04/28/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 70.32% | Needham | Gil Blum | → $7 | Reiterates | → Buy | Get Alert |
| 04/21/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 70.32% | Needham | Gil Blum | → $7 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 94.65% | Wells Fargo | Yanan Zhu | → $8 | Assumes | → Overweight | Get Alert |
| 03/08/2023 | AUTL | Buy Now | Autolus Therapeutics | $4.11 | 191.97% | Mizuho | Mara Goldstein | $18 → $12 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Autolus Therapeutics (AUTL)?
The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on April 12, 2024. The analyst firm set a price target for $9.00 expecting AUTL to rise to within 12 months (a possible 118.98% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Autolus Therapeutics (AUTL)?
The latest analyst rating for Autolus Therapeutics (NASDAQ: AUTL) was provided by Needham, and Autolus Therapeutics reiterated their buy rating.
When was the last upgrade for Autolus Therapeutics (AUTL)?
There is no last upgrade for Autolus Therapeutics.
When was the last downgrade for Autolus Therapeutics (AUTL)?
There is no last downgrade for Autolus Therapeutics.
When is the next analyst rating going to be posted or updated for Autolus Therapeutics (AUTL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Autolus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Autolus Therapeutics was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating Autolus Therapeutics (AUTL) correct?
While ratings are subjective and will change, the latest Autolus Therapeutics (AUTL) rating was a reiterated with a price target of $0.00 to $9.00. The current price Autolus Therapeutics (AUTL) is trading at is $4.11, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.